Proliferation characteristics of CD133+ cell population in colorectal cancer

Abstract

In this study, CD133+ subpopulations were isolated from 41 primary colorectal cancer tissues, the proliferation and cell cycle distribution of the cells were examined without in vitro expansion, and then compared to those of cell lines. The detection of CD133 in colorectal cancer tissues, isolation of CD133+ and CD133− epithelial subpopulations, Ki-67/DNA multiparameter assay and cell volume analysis were flow cytometrically conducted. The results showed that Ki-67 expression was correlated with CD133 level in primary cancer tissues, while cell cycle G2/M phase distribution or clinicopathological characteristics was not. In addition, the CD133+ cells showed larger cell volume and higher Ki-67 expression as compared with CD133− cells. But there was no statistically significant difference in G₂/M phase distribution between the two subpopulations. Our results demonstrated that the CD133+ subpopulation in colorectal cancer tissue contained more actively cycling and proliferating cells, which was not correlated to clinicopathological factors but might contribute to tumor progression and poor clinical outcome.

Keywords

CD133 / cancer stem cell / Ki-67 / cell cycle / tumor heterogeneity / colorectal cancer

References

[1] TirinoV., DesiderioV., d’AquinoR., et al.. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One, 2008, 3(10): e3469

[2] AillesL.E., WeissmanI.L.. Cancer stem cells in solid tumors. Curr Opin Biotechnol, 2007, 18(5): 460-466

[3] Al-HajjM., ClarkeM.F.. Self-renewal and solid tumor stem cells. Oncogene, 2004, 23(43): 7274-7282

[4] WeigmannA., CorbeilD., HellwigA., et al.. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA, 1997, 94(23): 12425-12430

[5] MiragliaS., GodfreyW., YinA.H., et al.. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood, 1997, 90(12): 5013-5021

[6] FargeasC.A., CorbeilD., HuttnerW.B.. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells, 2003, 21(4): 506-508

[7] KobariL., GiarratanaM. P. F., et al.. CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells. J Hematother Stem Cell Res, 2001, 10(2): 273-281

[8] ZhengW., WanY., MaX., et al.. Isolation of cultured endothelial progenitor cells in vitro from PBMCs and CD133(+) enriched cells. J Huazhong Univ Sci Technolog [Med Sci], 2010, 30(1): 18-24

[9] SinghS.K., HawkinsC., ClarkeI.D., et al.. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015): 396-401

[10] SinghS.K., ClarkeI.D., HideT., et al.. Cancer stem cells in nervous system tumors. Oncogene, 2004, 23(43): 7267-7273

[11] CollinsA.T., BerryP.A., HydeC., et al.. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 2005, 65(23): 10946-10951

[12] WeiC., GuominW., YujunL., et al.. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?. Cancer Biol Ther, 2007, 6(5): 763-768

[13] MaS., ChanK.W., HuL., et al.. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 2007, 132(7): 2542-2556

[14] YinS., LiJ., HuC., et al.. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer, 2007, 120(7): 1444-1450

[15] O’BrienC.A., PollettA., GallingerS., et al.. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 2007, 445(7123): 106-110

[16] Ricci-VitianiL., LombardiD.G., PilozziE., et al.. Identification and expansion of human colon-cancerinitiating cells. Nature, 2007, 445(7123): 111-115

[17] HermannP.C., HuberS.L., HerrlerT., et al.. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007, 1(3): 313-323

[18] ImmervollH., HoemD., SakariassenP.O., et al.. Expression of the stem cell marker CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer, 2008, 8: 48

[19] JakschM., MuneraJ., BajpaiR., et al.. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res, 2008, 68(19): 7882-7886

[20] XieD.X., YaoJ., ZhangP., et al.. Are progenitor cells pre-programmed for sequential cell cycles not requiring cyclins D and E and activation of Cdk2?. Cell Prolif, 2008, 41(2): 265-278

[21] JordanC.T., GuzmanM.L., NobleM.. Cancer stem cells. N Engl J Med, 2006, 355(12): 1253-1261

[22] HorstD., KrieglL., EngelJ., et al.. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer, 2008, 99(8): 1285-1289

[23] ShmelkovS.V., ButlerJ.M., HooperA.T., et al.. CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest, 2008, 118(6): 2111-2120

[24] LaBargeM.A., BissellM.J.. Is CD133 a marker of metastatic colon cancer stem cells?. J Clin Invest, 2008, 118(6): 2021-2024

[25] IetaK., TanakaF., HaraguchiN., et al.. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol, 2008, 15(2): 638-648

[26] MaY.L., PengJ.Y., ZhangP., et al.. Immunohistochemical analysis revealed CD34 and Ki67 protein expression as significant prognostic factors in colorectal cancer. Med Oncol, 2010, 27(2): 304-309

[27] DalerbaP., DyllaS.J., ParkI.K., et al.. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A, 2007, 104(24): 10158-10163

[28] ShiX., YuanX., TaoD., et al.. Analysis of DNA ploidy, cell cycle and Ki67 antigen in nasopharyngeal carcinoma by flow cytometry. J Huazhong Univ Sci Technol [Med Sci], 2005, 25(2): 198-201

[29] AraujoS.E., BernardoW.M., Habr-GamaA., et al.. DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum, 2007, 50(11): 1800-1810

[30] KusumbeA.P., BapatS.A.. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res, 2009, 69(24): 9245-9253